The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample
Oedegaard K, Alda M, Anand A, Andreassen O, Balaraman Y, Berrettini W, Bhattacharjee A, Brennand K, Burdick K, Calabrese J, Calkin C, Claasen A, Coryell W, Craig D, DeModena A, Frye M, Gage F, Gao K, Garnham J, Gershon E, Jakobsen P, Leckband S, McCarthy M, McInnis M, Maihofer A, Mertens J, Morken G, Nievergelt C, Nurnberger J, Pham S, Schoeyen H, Shekhtman T, Shilling P, Szelinger S, Tarwater B, Yao J, Zandi P, Kelsoe J. The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample. BMC Psychiatry 2016, 16: 129. PMID: 27150464, PMCID: PMC4857276, DOI: 10.1186/s12888-016-0732-x.Peer-Reviewed Original ResearchConceptsLithium monotherapyBipolar disorderLithium responseMechanism of actionClinical managementValproic acidLithium respondersSingle nucleotide polymorphismsMethods/designThis studyCox proportional hazards modelProspective study sampleLarge prospective cohortLarge prospective studiesClinical Global ImpressionInitiation of treatmentMood-stabilizing medicationsBipolar Disorder (STEP-BD) studyProportional hazards modelResults of treatmentCommon psychiatric disordersMEq/L.Genome-wide association studiesClinical relapseProspective cohortRemitting course